Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2009 1
2010 2
2011 3
2012 1
2013 2
2015 2
2016 4
2017 5
2018 9
2019 9
2020 5
2021 11
2022 13
2023 13
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215).
Zhao W, Lei J, Ke S, Chen Y, Xiao J, Tang Z, Wang L, Ren Y, Alnaggar M, Qiu H, Shi W, Yin L, Chen Y. Zhao W, et al. Among authors: qiu h. EClinicalMedicine. 2023 Nov 14;66:102315. doi: 10.1016/j.eclinm.2023.102315. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38024475 Free PMC article.
A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Tian Y, Shi Z, Wang C, Ke S, Qiu H, Zhao W, Wu Y, Chen J, Zhang Y, Chen Y. Tian Y, et al. Among authors: qiu h. Ann Surg Oncol. 2024 Feb;31(2):860-871. doi: 10.1245/s10434-023-14534-9. Epub 2023 Nov 10. Ann Surg Oncol. 2024. PMID: 37947979
Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.
Zhao W, Ke S, Cai X, Zuo Z, Shi W, Qiu H, Cai G, Gong Y, Wu Y, Ruan S, Chen Y. Zhao W, et al. Among authors: qiu h. Radiother Oncol. 2023 Jul;184:109679. doi: 10.1016/j.radonc.2023.109679. Epub 2023 Apr 25. Radiother Oncol. 2023. PMID: 37105302 Clinical Trial.
75 results